Gastrointestinal safety across the albiglutide development programme

In conclusion, albiglutide has an acceptable GI tolerability profile, with nausea and vomiting rates slightly higher than that for placebo but lower than those for liraglutide.

Source: Diabetes, Obesity and Metabolism - April 21, 2016 Category: Endocrinology Authors: Lawrence A. Leiter, Jason M. Mallory, Timothy H. Wilson, Rickey R. Reinhardt Tags: RESEARCH LETTER Source Type: research